Abstract
Two hundred patients, who underwent cadaveric kidney transplantation, were respectively treated with either anti-thymocyte, globulin (ATG) in 100 cases or with CsA in other patients, to prevent allograft acute rejection. They were observed for 3 months. The results of comparison with these two groups: renal recovery was shorter in the ATG group (3–10 days) than the CsA group (7–15 days), had a lower rate of acute rejection (18%) vs CsA group (47%), had no nephrotoxic patients whereas the CsA group had 6 patients (p < 0.05), and the same rate of hepatotoxicity and infection with CsA group (p > 0.05). IL-6 and SIL-2R had higher levels in the ATG group, it may be associated with ATG stimulating lymphocytes to release a number of cytokines. The value of ATG in preventing acute rejection will be analysed and discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Xiwen, B., Lixin, Y., Junjie, M., Jian, X. (1997). Preventing Cadaveric Grafted Kidney from Acute Rejection with Anti-Thymocyte Globulin. In: Touraine, J.L., Traeger, J., Bétuel, H., Dubernard, J.M., Revillard, J.P., Dupuy, C. (eds) Late Graft Loss. Transplantation and Clinical Immunology, vol 28. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5434-5_42
Download citation
DOI: https://doi.org/10.1007/978-94-011-5434-5_42
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6286-2
Online ISBN: 978-94-011-5434-5
eBook Packages: Springer Book Archive